<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002278</url>
  </required_header>
  <id_info>
    <org_study_id>038B</org_study_id>
    <secondary_id>JRD 64,433/1102</secondary_id>
    <nct_id>NCT00002278</nct_id>
  </id_info>
  <brief_title>A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS</brief_title>
  <official_title>28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial
      related diarrhea in AIDS patients who have been treated in the double-blind study # JRD
      64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with
      cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this
      protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cryptosporidiosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclazuril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT).

          -  Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose
             for 3 weeks or more.

          -  Aerosolized pentamidine.

          -  Nystatin for control of oropharyngeal infections. Nystatin must not be taken within
             two hours of diclazuril.

          -  Ganciclovir therapy only for CMV retinitis is permitted if the patient has been
             treated for at least 4 weeks prior to study entry and is stable on the drug.

          -  Loperamide may be taken if patient has been on long term loperamide prior to study
             entry but should not be started during the course of this protocol.

        Patients must have the following:

        Written informed consent given after the purpose and nature of the study, as well as the
        possible adverse effects related to the study drug, have been explained.

          -  Be willing and able to return for all subsequent weekly visits and the two week visit
             post completion of therapy (follow-up).

        Prior Medication:

        Allowed:

          -  Diclazuril.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Uncontrolled vomiting.

          -  Estimated survival less than 28 days.

          -  Other treatable enteric pathogens must be treated and eradicated prior to study entry.

        Concurrent Medication:

        Excluded:

          -  Amphotericin B.

          -  Other antibiotics or antiprotozoal drugs.

          -  Other investigational agents.

          -  Trimethoprim/sulfamethoxazole.

          -  Antifungal medications except nystatin.

          -  Ganciclovir for other than Cytomegalovirus (CMV) retinitis.

          -  Antidiarrheal agents other than patients on long term loperamide prior to study entry.

        Patients with the following are excluded:

          -  Undependable in following the instructions of the investigator.

          -  Not able to swallow capsules.

          -  Uncontrolled vomiting.

          -  Estimated survival less than 28 days.

        Prior Medication:

        Excluded:

          -  Diclazuril within 2 weeks of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1990</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Cryptosporidiosis</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>diclazuril</keyword>
  <keyword>Coccidiostats</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cryptosporidiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclazuril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

